U.S. STOCKS ON THE MOVE-Apollo Medical, MagnaChip, Dave & Buster's
Mustang Bio: Rises on positive early data from blood cancer therapy study
Brief: Mustang Bio Announces Updated Interim Phase 1/2 Data For MB-106 CD20-Targeted CAR T in Patients with Chronic Lymphocytic Leukemia
U.S. STOCKS ON THE MOVE-Tesla, Coinbase, Home Depot, CVS Health
U.S. STOCKS ON THE MOVE-Amazon.com, AT&T, Tesla, Agenus
Mustang Bio: Rises on dosing first patient in early-stage brain tumor therapy study
Brief: Mustang Bio And City Of Hope Announce First Patient Dosed In Phase 1 Clinical Trial Of MB-101
Mustang Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Mustang Bio Posts Q1 Loss Per Share Of $0.19
Mustang Bio: Up as FDA greenlights cancer drug trial
Brief: Mustang Bio Inc Files For Mixed Shelf Of Upto $200 Million - SEC Filing
Brief: Mustang Bio Reports Full-Year 2020 Financial Results And Recent Corporate Highlights
Brief: Mustang Bio Provides Updates On Its Lentiviral Gene Therapies For The Treatment Of X-Linked Severe Combined Immunodeficiency
Brief: Mustang Bio Announces Interim Phase 1/2 Data For MB-106 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
Brief: Mustang Bio Files Prospectus Supplement Related To Common Stock Offering Of Up To $100 Million
Brief: Mustang Bio Announces Positive Opinion From The European Medicines Agency On Orphan Drug Designation For Its Lentiviral Gene Therapy For The Treatment Of X-Linked Severe Combined Immunodeficiency
Brief: Mustang Bio Reports Third Quarter 2020 Financial Results And Recent Corporate Highlights
Brief: Mustang Bio Announces Mb-106 Data Selected For Presentation At The 62Nd American Society Of Hematology (Ash) Annual Meeting
Brief: Mustang Bio Announces Initial Phase 1 Data On MB-105 For Patients With PSCA-Positive Castration Resistant Prostate Cancer